Dott. Giovanni Salamano Studio Medico

Dott. Giovanni Salamano Studio Medico Da tre generazioni ci occupiamo della salute dei Vercellesi, come Medici di Famiglia dal 1921 ad ogg

 New in the January 29, 2026, issue of NEJM: ⁣⁣Olezarsen for Managing Severe Hypertriglyceridemia (phase 3 CORE-TIMI 72a...
31/01/2026

New in the January 29, 2026, issue of NEJM: ⁣

Olezarsen for Managing Severe Hypertriglyceridemia (phase 3 CORE-TIMI 72a and CORE2-TIMI 72b trials) ⁣

Tenecteplase in Acute Central Retinal Artery Occlusion (phase 3 TenCRAOS trial)⁣

Palbociclib for HR- and HER2-Positive Breast Cancer (phase 3 PATINA trial) ⁣

Etranacogene Dezaparvovec for Hemophilia B (phase 3 HOPE-B study) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among adults in the United Stat...
18/01/2026

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among adults in the United States and other countries. It occurs when deposits called drusen accumulate under the retina and retinal pigment epithelial (RPE) cells (swipe left for Key Concepts) over a lifetime, increasing with age in persons with genetic and environmental risk factors (seen in figure). Patients lose vision when the deposits damage the RPE and photoreceptor cells responsible for vision, either directly (resulting in geographic atrophy) or through the development of new blood vessels beneath the RPE or retina (subretinal neovascularization). An improved understanding of mechanisms that cause subretinal neovascularization led to groundbreaking treatments that interfere with vascular endothelial growth factor (anti-VEGF treatments) and are widely prescribed. However, anti-VEGF treatments do not prevent atrophy, and even with aggressive treatment, many patients with subretinal neovascularization eventually lose vision. Vision loss from geographic atrophy can also occur in the absence of neovascularization when photoreceptors, RPE cells, and the choriocapillaris vessels that supply blood to the outer retina degenerate. Complement inhibitors to slow the progression of geographic atrophy have received regulatory approval in the United States and Australia but not elsewhere, because monthly injections in the vitreous are required and the treatments do not improve vision; rather, they slow disease progression. Vitamin supplements have been shown to reduce the risk of vision loss from both neovascularization and geographic atrophy. However, no treatments have been shown to improve vision after geographic atrophy involves the fovea, located at the center of the macula. ⁣

In NEJM, Holz and colleagues report 12-month results for 32 patients with severe vision loss from AMD complicated by geographic atrophy who received a retinal prosthetic chip to restore vision. The scientific foundations for restoring vision loss in this manner are described in a new editorial by Jacque Duncan, MD. ⁣

Read the full editorial at NEJM.org (link in bio).⁣

 New in the January 15, 2026, issue of NEJM: ⁣⁣Management of Asymptomatic Carotid Stenosis (CREST-2 trials) ⁣⁣Vision Res...
18/01/2026

New in the January 15, 2026, issue of NEJM: ⁣

Management of Asymptomatic Carotid Stenosis (CREST-2 trials) ⁣

Vision Restoration in Geographic Atrophy Due to AMD (PRIMAvera trial): ⁣

Fremanezumab in Children with Episodic Migraine ⁣

CAR T-Cell Therapy for Autoimmune Hemolytic Anemia ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the January 8, 2026, issue of NEJM: ⁣⁣Evolocumab in Patients without Previous MI or Stroke (VESALIUS-CV trial) ⁣...
11/01/2026

New in the January 8, 2026, issue of NEJM: ⁣

Evolocumab in Patients without Previous MI or Stroke (VESALIUS-CV trial) ⁣

Fish Oil, Cardiovascular Events, and Hemodialysis (PISCES trial) ⁣

RSV Prefusion F Vaccine for Older Adults (DAN-RSV phase 4 trial) ⁣

Base-Edited CAR7 T Cells for T-Cell ALL⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the January 1, 2026, issue of NEJM: ⁣⁣Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase...
01/01/2026

New in the January 1, 2026, issue of NEJM: ⁣

Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) ⁣

Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) ⁣

Brain-Penetrant Enzyme Therapy for MPS II ⁣

Talquetamab and Teclistamab for Extramedullary Myeloma (RedirecTT-1 phase 2 study) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the December 18/25, issue of NEJM: ⁣⁣ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) ⁣⁣Ca...
01/01/2026

New in the December 18/25, issue of NEJM: ⁣

ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) ⁣

Cardiovascular Outcomes with Tirzepatide (SURPASS-CVOT trial) ⁣

Noninferiority of One HPV Vaccine Dose to Two Doses (ESCUDDO trial) ⁣

High-Dose Rifampin in Tuberculous Meningitis (HARVEST phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the December 11, 2025, issue of NEJM: ⁣⁣High-Dose Influenza Vaccine in Older Adults (DANFLU-2 trial) ⁣⁣High-Dose...
01/01/2026

New in the December 11, 2025, issue of NEJM: ⁣

High-Dose Influenza Vaccine in Older Adults (DANFLU-2 trial) ⁣

High-Dose Influenza Vaccine and Hospitalizations (GALFLU trial) ⁣

Ticagrelor and Aspirin after Coronary Surgery (TACSI trial) ⁣

Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the December 4, 2025, issue of NEJM: ⁣⁣Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) ⁣⁣Shunting...
01/01/2026

New in the December 4, 2025, issue of NEJM: ⁣

Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) ⁣

Shunting for Idiopathic Normal-Pressure Hydrocephalus (PENS trial) ⁣

Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the November 27, 2025, issue of NEJM: ⁣⁣Early Discontinuation of Aspirin after PCI (TARGET-FIRST trial) ⁣⁣Early ...
29/11/2025

New in the November 27, 2025, issue of NEJM: ⁣

Early Discontinuation of Aspirin after PCI (TARGET-FIRST trial) ⁣

Early Withdrawal of Aspirin after PCI (NEO-MINDSET trial) ⁣

Daily Mosnodenvir as Dengue Prophylaxis ⁣

CRISPR-Cas9 Targeting ANGPTL3⁣

Engasertib in Hereditary Hemorrhagic Telangiectasia ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 Food allergy is increasingly prevalent in developed countries, affecting approximately 10% of children in the United St...
29/11/2025

Food allergy is increasingly prevalent in developed countries, affecting approximately 10% of children in the United States. Immune sensitization (based on the detection of IgE specific for food proteins) to peanuts, eggs, milk, sesame, tree nuts, or seafood is a risk factor for food allergy, although not all sensitized persons have a reaction on exposure. The clinical signs and symptoms of food allergy include oral pruritus, abdominal pain, diarrhea, laryngeal obstruction, urticaria, wheezing, and hypotension. They are attributable to the food protein–induced activation of mast cells and basophils. Mast cells and basophils are the major effector cells of IgE-driven immediate hypersensitivity; they generate or release potent vasoactive and bronchoconstricting mediators. In the most extreme situation, food allergy can result in systemic anaphylaxis, a rapid-onset life-threatening event that can induce cardiovascular or respiratory compromise due to widespread activation of mast cells and basophils. Food allergy accounts for 30 to 50% of anaphylaxis in the United States. Contemporary advances in the prevention and treatment of food allergy include the introduction of peanut protein to the diet early in life, Food and Drug Administration ()–approved oral peanut immunotherapy, and monoclonal antibodies against IgE to prevent it from binding to cells and eliciting responses. Nonetheless, food allergy continues to cause substantial illness and anxiety, and anaphylaxis due to inadvertent ingestion remains prevalent. Mechanistic insights and new approaches to the management of food allergy are urgently needed. Studies recently reported by Hoyt et al. and Bachtel et al. therefore come as welcome news. ⁣

Continue reading the Clinical Implications of Basic Research article “A New Stage for Seasoned Actors — Food Anaphylaxis and the Cysteinyl Leukotrienes,” from and , at NEJM.org (link in bio). ⁣

NEJM

 New in the November 20, 2025, issue of NEJM: ⁣⁣Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) ⁣⁣Red...
29/11/2025

New in the November 20, 2025, issue of NEJM: ⁣

Potassium for High Risk of Ventricular Arrhythmias (POTCAST trial) ⁣

Reducing Antihypertensive Drugs in Nursing Home Residents (RETREAT-FRAIL trial) ⁣

Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) ⁣

Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial)⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 Pituitary tumors account for approximately 15% of intracranial neoplasms and may (in the case of macroadenomas, which h...
29/11/2025

Pituitary tumors account for approximately 15% of intracranial neoplasms and may (in the case of macroadenomas, which have a diameter >10 mm) cause compression of surrounding structures, as well as systemic symptoms. Acromegaly is the result of excess growth hormone secretion by generally benign adenomas arising in adult pituitary somatotrophs. Extrapituitary causes are exceedingly rare. The incidence of acromegaly is approximately 10 cases per 1 million persons. Roughly 20% of all pituitary tumors secrete growth hormone (somatotroph adenomas), and 95% appear to be sporadic, without known genetic causes. Approximately 25% of somatotroph adenomas also secrete prolactin. In a new article, Andrea Giustina, MD, and Annamaria Colao, MD, PhD, review current knowledge of the pathophysiology and pathogenesis of acromegaly, as well as its clinical features, diagnosis, treatment, and disease course, focusing on the general clinician’s key role in early diagnosis and management. ⁣

Read the Review Article “Acromegaly,” from , IRCCS San Raffaele Hospital (.raffaele), and , at NEJM.org (link in bio). ⁣

Otolaryngology Cardiology NEJM

Indirizzo

Piazza Solferino N. 3
Vercelli
13100

Orario di apertura

Lunedì 17:00 - 19:00
Martedì 17:00 - 19:00
Mercoledì 10:00 - 12:00
Giovedì 10:00 - 12:00
Venerdì 17:00 - 19:00

Telefono

+393345713761

Sito Web

https://www.miodottore.it/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Dott. Giovanni Salamano Studio Medico pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Dott. Giovanni Salamano Studio Medico:

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

A little help to Health in rural town.

Da tre generazioni lo Studio Medico Salamano si occupa della salute de

i pazienti Vercellesi. Zona posta tra le metropoli di Torino e Milano esattamente a metà strada tra le due città più importanti del Nord Italia è famosa nel mondo agricolo per la presenza della risicoltura resa possibile da Camillo Benso Conte di Cavour, primo ministro del Regno Sabaudo che qui regnava. La presenza del fiume Po e dei suoi maggiori affluenti dalle Alpi che circondano il Piemonte ha reso possibile nei primi dell’800 la costruzione di canali che permettono una abbondante irrigazione di queste terre, prima paludose e bonificate dai Monaci Cistercensi nell’epoca Medioevale intorno al 1200 - 1300 fondando importanti Abazie che facevano capo all’Arcidiocesi di Vercelli. Proprio a causa della posizione immersa nella pianura padana e nel suo clima afoso d’estate e nebbioso d’inverno, questa regione ha una insolitamente elevata percentuale di pazienti sofferenti di osteopatie ( i cosiddetti Reumatismi ) e malattie infettive dell’apparato respiratorio. Recentemente con l’aumento della vita media grazie ai progressi principalmente in capo cardiovascolare si sta assistendo ad un aumento quasi esponenziale dei casi di neoplasie dell’albero respiratorio, dell’apparato gastroenterico e urinario. Il problema dell’inquinamento atmosferico è in questa zona particolarmente evidente per le scarse correnti di aria che possano pulire e rinnovare l’aria ed il puvuscolo atmosferico stagnante in questa regione nonostante sia a carattere rurale e non industriale come le vicine Torino e Milano. Un particolare evidente nel recente passato è la particolare incidenza di Leptospirosi dovuta alla presenza di acqua stagnante nelle risaie dove le contadine lavoravano a piedi scalzi. Tuttavia anche l’artrite reumatoide e le malattie reumatiche in genere hanno una elevata incidenza tanto che fino a pochi anni fa nell’’Ospedale Sant’Andrea di Vercelli era presente un reparto di Reumatologia ( uno dei pochi in Italia e purtroppo recentemente eliminato ). Per tali motivi prima mio nonno Giovanni Dott Salamano ( Nino ) poi mio padre Andre Dott Salamano ed infine il sottoscritto Giovanni Dott Salamano abbiamo dedicato la nostra ”vita“ alla cura ed allo studio delle malattie infettive ( Nonno Nino ), Reumatiche ( papà Andrea ) ed osteometaboliche ( il sottoscritto ), pur mantenendo l’attenzione sulla Medicina Generale che il Medico di Famiglia deve saper affrontare.